You searched for "AMM"
A phase 3 randomised trial of nicotinamide for skin cancer chemoprevention
To B3, or not to B3? That was the question asked in this controlled trial in which the authors were able to show that oral nicotinamide (vitamin B3) is able to reduce further skin cancer development in high risk patients....
Surgical correction of lacrimal gland prolapse
This is a systematic review of published literature on the management of lacrimal gland prolapse or ptosis. The authors found 16 publications which contained a description of any surgical correction of a prolapsed lacrimal gland, comprising seven case reports, four...
Exploring the potential of neurodegenerative disease screening within age-related eye disease research
The authors recruited healthy controls aged between 60 and 75-years-old, previously enrolled into a registry as patients following cataract surgery without age-related macular degeneration (AMD). Exclusion criteria included dense cataract, retinal disease, ocular inflammatory disease, moderate glaucoma, optic neuropathy, cancer,...
PRN Ranibizumab verses continuous aflibercept in UK clinical practice
This was a multicentre (21 UK hospitals), national EMR study on treatment naïve nAMD eyes, undergoing predominantly as needed (PRN) Ranibizumab or continuous (fixed or treat and extend - (F/TE)) Aflibercept (Af). The primary outcome was change in vision at...
Macular atrophy with aflibercept
The authors of this paper set out to investigate the prevalence of macular atrophy in treatment-naive patients with neovascular AMD undergoing aflibercept monotherapy (three monthly loading injections followed by subsequent treatment every two months). Case notes over a three year...
Systemic pharmacology of intravitreal anti-VEGF
This study aimed to evaluate and compare serum drug concentrations and plasma free-VEGF concentrations in patients with AMD, DME, or RVO receiving intravitreal injections of aflibercept, bevacizumab or ranibizumab. This prospective study enrolled patients from several offices of a single...
Data update for leading causes of CVI in England and Wales
In this article the authors present an epidemiological update, based on certifiable visual impairment (CVI) registration for figures for sight impairment (SI) in England and Wales from the last report of 2007-2008 to the current data for April 2012 to...Uveal melanoma
Uveal melanoma is the most common primary intraocular tumour. However, they are still rare, with an incidence of 2-8 per million [1]. The presence of a choroidal naevus is a risk factor for uveal melanoma [1]. Patients with choroidal lesions...Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice
The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...Technology in ophthalmology – a promising future and what we need to know about the regulations
Undoubtedly, ophthalmology is one of the greatest sources of inspiration for technological progress in medicine. Thus far, we have seen remarkable advancements in the technology used by ophthalmologists across all subspecialties. From simplifying common procedures, to treating previously incurable conditions,...
The dynamic nature of orbital cavernous haemangiomas
This paper seeks to address the question of how much do orbital cavernous haemangiomas actually change over time, and if there are any identifiable factors which can predict which lesions will grow and which will remain stable. In particular, if...
